# Licopyranocoumarin (Glycyrrhiza uralensis)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/licopyranocoumarin-glycyrrhiza-uralensis
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-02
**Evidence Score:** 1 / 10
**Category:** Compound
**Also Known As:** licorice pyranocumarin fraction, LPC, Licopyranocoumarin (Glycyrrhiza spp.), lico-pyranocoumarin, Licopyranocoumarin (Glycyrrhiza uralensis / Glycyrrhiza glabra), Glycyrrhiza uralensis pyranocumarin, Licopyranocoumarin (Glycyrrhiza uralensis / G. glabra)

## Overview

Licopyranocoumarin is a pyranocumarin isolated from Glycyrrhiza uralensis that exerts [neuroprotective effect](/ingredients/condition/cognitive)s by attenuating intracellular [reactive oxygen species](/ingredients/condition/antioxidant) accumulation and inhibiting sub-G1 apoptotic signaling, and also demonstrates anti-HIV activity through inhibition of syncytium (giant cell) formation. In the most quantified preclinical model, LPC reduced MPP+-induced intracellular ROS from 177±16.5% to 164±15.7% of control at 3 µM (p<0.01) and significantly decreased apoptotic cell death in NGF-differentiated PC12D cells at 1–10 µM over 48 hours, though no human clinical data currently exist.

## Health Benefits

- **Neuroprotection (Parkinson's Disease Model)**: LPC reduces MPP+-induced neuronal cell death and sub-G1 apoptotic accumulation in NGF-differentiated PC12D cells at 1–10 µM over 48 hours, positioning it as a candidate [neuroprotective](/ingredients/condition/cognitive) agent in [dopamine](/ingredients/condition/mood)rgic degeneration models.
- **[Reactive Oxygen Species](/ingredients/condition/antioxidant) Attenuation**: At 3 µM, LPC lowers MPP+-induced intracellular ROS levels from 177±16.5% to 164±15.7% of control (p<0.01) as measured by CM-H2DCFDA flow cytometry, suggesting an indirect antioxidant mechanism rather than direct radical scavenging.
- **Anti-HIV Activity**: LPC inhibits the formation of HIV-induced syncytia (multinucleated giant cells), a hallmark of HIV-1 cytopathogenicity, making it a subject of interest in [antiviral](/ingredients/condition/immune-support) research targeting viral cell-to-cell fusion mechanisms.
- **CYP3A4 Inhibition**: LPC demonstrates inhibitory activity against cytochrome P450 3A4, the enzyme responsible for metabolizing approximately 50% of pharmaceutical drugs, indicating potential pharmacokinetic modulation activity.
- **Aryl Hydrocarbon Receptor (AhR) Antagonism**: LPC acts as an antagonist at the aryl hydrocarbon receptor, a ligand-activated transcription factor involved in xenobiotic [metabolism](/ingredients/condition/weight-management), immune regulation, and [inflammatory](/ingredients/condition/inflammation) signaling pathways.
- **Contribution to Licorice's Antiviral Profile**: As part of the phenolic coumarin fraction of G. uralensis alongside glycycoumarin and licocoumarone, LPC contributes to the broad-spectrum antiviral activities traditionally attributed to licorice root preparations in East Asian medicine.

## Mechanism of Action

Licopyranocoumarin's [neuroprotective](/ingredients/condition/cognitive) mechanism operates through an indirect antioxidant pathway: rather than directly scavenging [free radical](/ingredients/condition/antioxidant)s (it shows less than 10% inhibition in β-carotene bleaching and negligible DPPH scavenging at 30 µM), it suppresses intracellular ROS generation triggered by the [mitochondrial](/ingredients/condition/energy) complex I inhibitor MPP+, likely by modulating upstream signaling cascades that govern mitochondrial electron transport chain dysfunction. LPC inhibits CYP3A4 enzymatic activity, which may alter the metabolic fate of endogenous and exogenous substrates, and functions as an antagonist at the aryl hydrocarbon receptor (AhR), thereby potentially suppressing AhR-driven pro-[inflammatory](/ingredients/condition/inflammation) and xenobiotic-responsive gene transcription. Its anti-HIV mechanism is attributed to inhibition of syncytium formation—the HIV-1-mediated fusion of infected and uninfected CD4+ T cells into giant multinucleated cells—though the precise molecular target (e.g., gp120/gp41 envelope protein interaction, CD4 receptor blockade, or downstream fusion machinery) has not been fully characterized in published literature. The compound's pyranocumarin scaffold, which shares structural features with known [antiviral](/ingredients/condition/immune-support) and enzyme-inhibiting coumarins, is believed to underpin these multitarget activities.

## Clinical Summary

No clinical trials have been conducted on licopyranocoumarin in human subjects, and no data from animal efficacy models beyond cell-line experiments are documented in available sources. The compound has been studied exclusively in vitro using PC12D neuronal cells (Parkinson's model), HepG2 hepatocellular cells, and A549 lung epithelial cells, along with [antiviral](/ingredients/condition/immune-support) and enzyme inhibition assays. The quantified outcomes—ROS reduction at 3 µM (p<0.01), apoptosis inhibition at 1–10 µM, and CYP3A4 inhibitory activity—represent biological proof-of-concept rather than clinically validated effects. Confidence in any therapeutic application for humans remains very low pending pharmacokinetic studies, in vivo efficacy models, and eventual clinical investigation.

## Nutritional Profile

Licopyranocoumarin is a discrete low-molecular-weight polyphenolic compound belonging to the pyranocumarin subclass of coumarins and does not possess a conventional nutritional profile in terms of macronutrients, vitamins, or dietary minerals. Its chemical structure features a fused pyran-coumarin bicyclic scaffold characteristic of plant secondary metabolites, contributing to its planar aromatic character and lipophilicity that facilitates membrane penetration and intracellular target engagement. Within G. uralensis root, LPC is a minor constituent at approximately 0.022 mg per gram of dried root (calculated from reported extraction yields of 10.8 mg from 50 g), alongside dominant bioactives including glycyrrhizin (2–25 mg/g), liquiritin, isoliquiritin, and multiple flavonoids. Bioavailability of LPC has not been studied; however, the lipophilic pyranocumarin scaffold suggests potential for passive intestinal absorption, while coumarin compounds as a class are known to undergo hepatic first-pass [metabolism](/ingredients/condition/weight-management) involving CYP450 enzymes — an interaction potentially complicated by LPC's own CYP3A4 inhibitory activity.

## Dosage & Preparation

- **Laboratory Extraction (Research Grade)**: Isolated from dried G. uralensis root powder (50 g) by 90% ethanol extraction, pH adjustment to 7.0, ethyl acetate liquid-liquid partitioning (yield ~3.76 g crude residue), followed by ODS-HPLC purification with 40% aqueous acetonitrile mobile phase; this method yields approximately 10.8 mg of pure LPC per 50 g starting material.
- **In Vitro Effective Concentration**: [Neuroprotective effect](/ingredients/condition/cognitive)s observed at 1–10 µM in cell culture models; ROS attenuation significant at 3 µM — these are cell culture concentrations and cannot be directly extrapolated to human supplemental doses.
- **No Commercial Supplement Form Available**: LPC is not currently available as a standardized dietary supplement, nutraceutical, or pharmaceutical preparation; it exists only as a research chemical isolated in academic and pharmaceutical discovery contexts.
- **Traditional Licorice Root Preparations**: Glycyrrhiza uralensis root decoctions (3–15 g dried root in traditional Chinese medicine), water extracts, and standardized licorice root extracts contain LPC as one minor constituent among many, but LPC content in these preparations has not been quantified for end-users.
- **Timing/Administration Notes**: No dosing frequency, timing, or route of administration recommendations exist for LPC due to the complete absence of clinical or pharmacokinetic data.

## Safety & Drug Interactions

No formal safety studies, toxicological assessments, maximum tolerated dose data, or adverse event reports exist for licopyranocoumarin as an isolated compound, making it impossible to establish a safety profile beyond the absence of observed cytotoxicity in the cell concentrations used in neuroprotection experiments (1–10 µM). The most clinically significant pharmacological safety concern is LPC's documented CYP3A4 inhibitory activity, which theoretically could elevate plasma concentrations of CYP3A4-metabolized drugs (including statins, calcium channel blockers, immunosuppressants, HIV protease inhibitors, and certain benzodiazepines) if LPC were to reach relevant systemic concentrations — however, no clinical drug interaction studies have been conducted. Licorice root as a whole botanical raises well-documented safety concerns including glycyrrhizin-mediated pseudoaldosteronism (hypertension, hypokalemia, edema) at doses above 100 mg glycyrrhizin/day, but these effects are attributed to glycyrrhizin rather than LPC specifically. Given the complete absence of human safety data, pregnancy and lactation guidance cannot be provided for LPC, and use beyond whole licorice root in traditional doses is not established; isolated LPC should be considered a research compound only.

## Scientific Research

The entirety of published evidence for licopyranocoumarin derives from preclinical in vitro and cell-based studies, with no human clinical trials, animal pharmacokinetic studies, or randomized controlled trials reported as of available literature. The most detailed mechanistic work employed NGF-differentiated PC12D cells (a rat pheochromocytoma-derived Parkinson's model) treated with MPP+ as a neurotoxin, with LPC tested at 1–10 µM over 48 hours across three independent experiments with statistical significance at p<0.01 versus MPP+-only controls. Anti-HIV activity and CYP3A4 inhibition were identified through bioassay-guided fractionation of G. uralensis ethyl acetate extracts, a discovery-phase methodology that establishes activity but does not quantify potency parameters such as IC50 values or selectivity indices in the available summaries. The evidence base must be characterized as early-stage and exploratory; while the cell-based findings are internally consistent and methodologically described with appropriate controls, the absence of in vivo pharmacokinetic data, dose-response characterization in whole organisms, and any translational clinical work means that no efficacy conclusions applicable to human health can be drawn.

## Historical & Cultural Context

Glycyrrhiza uralensis (Gan Cao, 甘草) occupies one of the most prominent positions in the classical Chinese materia medica, documented in the Shennong Bencao Jing (Divine Farmer's Classic of Materia Medica, ~200 CE) as a superior-grade herb used to harmonize herbal formulas, tonify the spleen and stomach, resolve toxicity, and moisten the lungs. Licorice root preparations featuring G. uralensis were foundational in Kampo (Japanese traditional medicine) and Traditional Chinese Medicine (TCM), employed in hundreds of classical formulas such as Gan Cao Tang and Shao Yao Gan Cao Tang for antispasmodic, [anti-inflammatory](/ingredients/condition/inflammation), and [antiviral](/ingredients/condition/immune-support) indications. Licopyranocoumarin as a discrete chemical entity was not historically identified or employed; traditional practitioners worked with whole-root decoctions and did not possess the analytical tools to isolate individual coumarin constituents, so LPC's contribution to historical therapeutic effects can only be retrospectively inferred. The compound was identified through modern bioassay-guided fractionation specifically targeting [neuroprotective](/ingredients/condition/cognitive) activity, representing the intersection of ethnopharmacological leads and contemporary drug discovery methodology.

## Synergistic Combinations

No formally studied synergistic combinations for licopyranocoumarin exist in the published literature; however, its co-occurrence in G. uralensis extracts with glycycoumarin (a PPAR-γ activator at 5 µM), glycyrurol, and licocoumarone suggests that the coumarin fraction of licorice may exert complementary [neuroprotective](/ingredients/condition/cognitive) and [anti-inflammatory](/ingredients/condition/inflammation) effects through parallel but mechanistically distinct pathways. LPC's indirect ROS suppression could theoretically complement direct antioxidant compounds such as ascorbic acid, tocopherols, or resveratrol in neuroprotective stacks, as LPC addresses upstream [mitochondrial](/ingredients/condition/energy) ROS generation while classical antioxidants scavenge downstream [free radical](/ingredients/condition/antioxidant)s — a combination approach that has conceptual precedent in Parkinson's disease research but has not been tested with LPC specifically. Given LPC's CYP3A4 inhibitory activity, co-administration with other CYP3A4 substrates or inhibitors (e.g., piperine from black pepper, bergamottin from grapefruit) should be approached cautiously due to potential pharmacokinetic amplification rather than pharmacodynamic synergy.

## Frequently Asked Questions

### What is licopyranocoumarin and where does it come from?

Licopyranocoumarin (LPC) is a pyranocumarin-class polyphenolic compound isolated exclusively from the dried root of Glycyrrhiza uralensis (Chinese licorice), a species native to northern China and Central Asia. It has not been detected in the related licorice species G. glabra or G. inflata, making G. uralensis its unique botanical source. It is identified as a minor constituent within the plant's phenolic fraction alongside glycycoumarin, licocoumarone, and glycyrurol.

### Does licopyranocoumarin have anti-HIV properties?

Yes, licopyranocoumarin has demonstrated anti-HIV activity in preclinical studies through inhibition of syncytium formation — the process by which HIV-1 causes infected and uninfected CD4+ T cells to fuse into non-functional multinucleated giant cells, a key mechanism of HIV cytopathogenicity. This activity was identified during bioassay-guided fractionation of G. uralensis ethyl acetate extracts. However, all evidence is from laboratory cell-based assays; no clinical trials in HIV-positive humans have been conducted.

### What are the neuroprotective effects of licopyranocoumarin?

In NGF-differentiated PC12D cells (a dopaminergic neuron model used in Parkinson's disease research), LPC reduced MPP+-induced neuronal death and sub-G1 apoptotic accumulation at concentrations of 1–10 µM over 48 hours (p<0.01 versus MPP+-only controls). At 3 µM specifically, LPC lowered intracellular ROS from 177±16.5% to 164±15.7% of control values, measured by CM-H2DCFDA flow cytometry. Importantly, this protection is not due to direct antioxidant radical scavenging, as LPC shows negligible DPPH and β-carotene bleaching inhibition, suggesting an indirect mechanism targeting ROS-generating pathways.

### Is licopyranocoumarin safe to take as a supplement?

Licopyranocoumarin is not currently available as a consumer dietary supplement and has no established safety profile, dose limits, or human clinical data. The primary pharmacological safety concern identified in preclinical research is its CYP3A4 inhibitory activity, which could theoretically increase blood levels of many commonly prescribed medications including statins, certain blood pressure medications, and immunosuppressants. Until pharmacokinetic, toxicological, and clinical studies are completed, LPC should be regarded strictly as a research-stage compound and not used for self-supplementation.

### How is licopyranocoumarin different from glycyrrhizin in licorice?

Glycyrrhizin is the principal triterpene saponin in licorice root, present at high concentrations (2–25 mg/g dried root) and responsible for licorice's characteristic sweetness as well as its most well-documented risks — namely pseudoaldosteronism causing hypertension and hypokalemia with chronic high-dose consumption. Licopyranocoumarin belongs to an entirely different chemical class (pyranocumarins) and is present in far lower amounts (~0.022 mg/g dried root), with a distinct activity profile focused on neuroprotection, anti-HIV syncytium inhibition, and CYP3A4 modulation. The two compounds are structurally unrelated and exert their biological effects through entirely different molecular mechanisms.

### What does research show about licopyranocoumarin's effectiveness for Parkinson's disease?

In vitro studies using dopaminergic cell models show that licopyranocoumarin reduces MPP+-induced neuronal death and apoptosis at concentrations of 1–10 µM, suggesting potential neuroprotective activity in Parkinson's-related degeneration. At 3 µM, it significantly lowers reactive oxygen species (ROS) levels that are implicated in dopaminergic cell damage. However, current evidence is limited to laboratory cell studies and has not yet advanced to human clinical trials, so efficacy in living patients remains unproven.

### How does licopyranocoumarin reduce oxidative stress at the cellular level?

Licopyranocoumarin works by attenuating intracellular reactive oxygen species (ROS) generated during dopaminergic stress, lowering ROS levels dramatically in cell culture models exposed to neurotoxic agents like MPP+. This antioxidant mechanism appears to protect nerve cells from the oxidative damage that contributes to neuronal death and apoptosis. The ROS-reduction effect occurs at relatively low micromolar concentrations, suggesting potent antioxidant activity specific to neuronal tissue.

### Who might benefit most from licopyranocoumarin supplementation based on current research?

Based on neuroprotection studies, individuals interested in supporting dopaminergic function and mitigating oxidative neuronal stress—such as those concerned about age-related cognitive decline or neurodegenerative conditions—represent the primary research-identified population. However, the evidence base remains confined to in vitro cell models, so clinical relevance to humans has not been established. Anyone considering supplementation should consult a healthcare provider, especially those with existing neurological conditions or taking medications affecting dopamine pathways.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*